GlassScriptPhysician profile
Millicent Amankwah
NPI 1881071223
$3,323.75
in general payments reported to CMS, 2019-2025
40 companies · $1,061 in 2025
The $1,061 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.32 · 2022: $242 · 2023: $741 · 2024: $1,261 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,863 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.43 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $441.57 | 2022-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $332.02 | 2022-2025 | Lynparza, Calquence, Enhertu |
| Glaxosmithkline, LLC. | $326.53 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $228.00 | 2023-2025 | |
| Janssen Biotech, INC. | $222.53 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $219.73 | 2024-2025 | |
| Genentech USA, INC. | $194.22 | 2023-2025 | Tecentriq, Phesgo, Itovebi |
| Pfizer INC. | $162.33 | 2024-2025 | |
| Stemline Therapeutics INC. | $105.50 | 2023-2025 | Orserdu |
| Celgene Corporation | $79.69 | 2022-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $79.41 | 2024-2025 | Vyloy, Xospata, Padcev |
| E.R. Squibb & Sons, L.L.C. | $77.71 | 2022-2024 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $70.23 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $69.09 | 2023-2025 | Libtayo |
| Eisai INC. | $50.98 | 2022-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millicent Amankwah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.